QUOTE AND NEWS
PR Newswire  Nov 6  Comment 
NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the
PR Newswire  Nov 4  Comment 
NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit being
PR Newswire  Oct 29  Comment 
NEW YORK, Oct 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference taking
StreetInsider.com  Oct 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Keryx+Bio+%28KERX%29+Announces+Perifosine+Phase+2+for+Chronic+and+Small+Lymphocytic+Leukemia/5004186.html for the full story.
Stock Blog Hub  Oct 3  Comment 
Last week, Keryx Biopharmaceuticals, Inc. (KERX) announced that its renal cancer drug KRX-0401 (perifosine) met both primary and secondary endpoints in a mid-stage trial. KRX-0401 is in-licensed by Keryx from Aeterna Zentaris Inc. (AEZS) in the...
PR Newswire  Sep 25  Comment 
NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX), has entered into definitive agreements to sell 8 million shares of its common stock at a price per share of $2.50 pursuant to a registered
TheStreet.com  Sep 24  Comment 
Keryx Biopharmaceuticals was trading lower on above-average volume after the company announced successful results of a kidney-disease drug trial.
StreetInsider.com  Sep 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Keryx+Biopharmaceuticals+%28KERX%29+Files+To+Offer+%2440M+In+Stock+and+Warrants/4965547.html for the full story.
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 


 
KERX AT A GLANCE
P/E 15.5AVG
EV/EBITDA 23.8HIGH
ROA 9.5%VERY HIGH
ROE 38.9%HIGH
Debt to Equity 0.605AVG
Current Ratio 2.72VERY LOW
Interest Coverage Ratio -3.33AVG
 
 
 
 
 
 
 
 



References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki